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WHAT’S ALREADY KNOWN?  
High-mobility group box 1 (HMGB1) is a marker of both tissue injury and innate immune 
response.  It’s elevation in serum of patients with  serious cutaneous adverse drug 
reactions has been reported previously but to date no analysis of its distribution in 
Stevens-Johnson syndrome / toxic epidermal necrolysis (SJS/TEN) patient blister-fluid 
and skin biopsy tissue has been described. 
 
WHAT DOES THIS STUDY ADD?  
This study confirms serum HMGB1 elevation in SJS/TEN in 3 independent cohorts. 
Additionally, it reports, for the first time: a) super-elevation of HMGB1 in blister-fluid and 
b) significantly decreased epidermal expression in pre-blistered SJS/TEN skin with 
suprabasal retention.  This is highly distinct from healthy or maculopapular exanthem 
skin and may represent a viable diagnostic tool.  
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ABSTRACT (250 WORDS) 
High-mobility group box 1 (HMGB1) is a damage-associated molecular-pattern protein 
indicative of cell/tissue injury and innate immune response. Stevens-Johnson syndrome 
(SJS)/toxic epidermal necrolysis (TEN) are serious, immune-mediated skin-blistering 
conditions characterised by widespread keratinocyte death and epidermal detachment.  
The purpose of the study was to determine: a) serum and/or blister-fluid total HMGB1 
levels in independent SJS/TEN cohorts: and b) HMGB1 expression in formalin-fixed, 
paraffin-embedded SJS/TEN skin vs. healthy and maculopapular exanthema (MPE). 
Total serum HMGB1 was quantified by enzyme-linked immunosorbent assay (ELISA) in 
3 cohorts: i) Malawian, nevirapine-induced hypersensitivity (51 cases, 102 tolerant); ii) 
Taiwanese SJS/TEN (n=73) (acute, maximal and recovery stage); iii) Spanish SJS/TEN 
(n=23) (acute reaction (blister-fluid (n=13)).  FFPE skin (5 healthy, 7 maculopapular 
exanthema (MPE), 7 SJS/TEN) was immunohistochemically (IHC) stained and semi-
quantitatively assessed for HMGB1 expression.   
Serum total HMGB1 was not significantly elevated in nevirapine-induced SJS/TEN 
(3.98ng/ml±2.17), MPE (3.92ng/ml±2.75) or DRESS (4.73ng/ml±3.00)) patients vs. 
tolerant controls (2.97ng/ml±3.00).  HMGB1 was significantly elevated in Taiwanese 
SJS/TEN patients, highest during the acute phase 32.6ng/ml±26.6 vs. maximal 
(19.7ng/ml±23.2; p=0.007) and recovery (24.6ng/ml±25.3; p=0.027) phases.  In blister 
fluid from Spanish SJS/TEN patients, HMGB1 (486.8ng/ml±687.9) was significantly 
higher than in serum (8.8ng/ml±7.6; p<0.0005).  Pre-blistered SJS/TEN skin 
demonstrated decreased epidermal nuclear HMGB1 expression in upper epidermis vs. 
healthy or MPE skin but retained basal/suprabasal expression. 
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Epidermal HMGB1 expression was decreased in SJS/TEN skin which may account for 
elevated serum and blister-fluid levels.  Retained basal/suprabasal epidermal HMGB1 
expression, from resident keratinocytes/ infiltrating inflammatory cells, may exacerbate 
localised injury in SJS/TEN, though further evaluation is required. 
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INTRODUCTION 
Stevens-Johnson syndrome (SJS)/ toxic epidermal necrolysis (TEN) is characterised by 
blistering of the skin and mucosal membranes with significant areas of skin detachment 
(up to 10% for SJS and >30% for TEN).  Though rare (6.52 cases per million patient 
years 1), SJS/TEN can have a severe impact on patients with a significant mortality rate 
and many suffering from long-term debilitating sequelae, including blindness.  In 
addition, SJS/TEN can be a resource burden on healthcare systems with the average 
hospital stay estimated at 7-12.6 days of which 1.7-4.9 days are spent in intensive 
treatment units 2. 
Drugs are amongst the commonest causes of SJS/TEN.  A number of predictive genetic 
markers for drug specific SJS/TEN have been identified 3.  Several serum protein 
markers are elevated in SJS/TEN patients at the time of the reaction and have the 
potential to act as prognostic or diagnostic markers. These include granulysin 4, Fas 
ligand 5, and more recently interleukin 15 6.  However, Nakajima et al 7 suggested that 
while granulysin and Fas ligand are possible candidate biomarkers, the duration of 
elevation is limited and therefore false negative results for SJS/TEN are a possibility. 
High Mobility Group Box-1 (HMGB1) is an example of a Damage Associated Molecular 
Pattern molecule (DAMP) which is critical in linking cell death to inflammation and in 
the progression of disease. HMGB1 sits at the intersection between infectious and 
sterile inflammation. It is actively released in an acetylated form from activated immune 
cells and passively released in the non-acetylated form during necrotic cell death 8.  
Previous studies have shown that total HMGB1 is significantly elevated in serum from 
patients with drug reaction with eosinophilia and systemic symptoms (DRESS) 9 and 
drug-induced SJS 7, at the time of the reaction and may discriminate between serious 
6 
 
cutaneous drug eruptions and milder phenotypes (MPE). 
The aim of this study was to assess total HMGB1 levels in serum samples from 3 
independent cohorts of SJS/TEN patients, as well as from blister fluid in a sub-set of 
patients. We have also evaluated HMGB1 expression levels and distribution in formalin-
fixed, paraffin embedded skin biopsy samples from SJS/TEN patients. 
 
PATIENTS AND METHODS 
Samples from 3 independent SJS/TEN patient cohorts were brought together for the 
purpose of this study: 
Nevirapine Patient Cohort 
Patients were prospectively recruited as previously described 10 after informed consent.  
The study was approved by the research ethics committees of the College of Medicine, 
Malawi, and Liverpool School of Tropical Medicine. Briefly, the study recruited 1117 
antiretroviral-naive HIV-positive patients from the Queen Elizabeth Central Hospital, 
Blantyre, Malawi, between March 2007 and December 2008.  All were self-reported black-
African, over the age of 16, had no baseline jaundice, and gave informed consent.  All 
patients were diagnosed as HIV clinical stage 3/4 or had a CD4+ count <250 cells/µL and 
were treated with fixed dose NVP, lamivudine and stavudine with follow up over 26 
weeks.  CD4+ counts and liver function test were monitored at 0, 6, 14 and 18 weeks.  A 
total of 51 patients presented with NVP-induced cutaneous hypersensitivity fulfilling the 
criteria of one or more of the following phenotypes: 
 Maculopapular exanthema (MPE) with no systemic manifestations and improvement 
only on stopping treatment. 
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 Drug reaction eosinophilia with systemic symptoms (DRESS): widespread rash with 
systemic manifestations (i.e. fever, cough or abnormal liver function tests (LFTs)). 
 SJS: extensive rash, affecting ≥2 mucous membranes or blistering eruptions affecting 
<10% of body surface area. 
 TEN: blistering rash affecting >30% of body surface area and ≥2 mucous membranes.  
Patients with 10-30% affected body surface area had the overlap syndrome. 
Each of the 51 hypersensitivity cases were age and gender matched to 2 NVP-tolerant 
HIV-positive controls (n=102).  Blood samples were taken from patients prior to 
commencement of NVP treatment (0 weeks) and then at 2, 6, 10, 14, 18 and 20 weeks.  In 
patients where a hypersensitivity reaction occurred, a sample was taken at the time of the 
first presentation (acute reaction) and no further sample taken thereafter as the patient 
was discontinued from the study.  For comparison to adverse reaction samples, tolerant 
control samples at the 2 week time-point were used. Serum was isolated and frozen at -
80°C.  The purpose of analysing this cohort was to determine variability in serum HMGB1 
levels between different types of cutaneous adverse drug reactions during the acute 
phase compared to tolerant controls. 
 
Taiwanese SJS/TEN Cohort 
A total of 73 Han Chinese patients with SJS/TEN (Supplementary Table 1) were enrolled 
from 2009 to 2015 at Chang Gung Memorial Hospital in Taiwan that received referrals 
from other hospitals nationally (including National Taiwan University Hospital, Taichung 
Veterans General Hospital, National Cheng Kung University Hospital, Kaohsiung Medical 
University, and Chung-Ho Memorial Hospital). SJS/TEN was characterized by rapidly 
developing blistering exanthema with purpuric macules, accompanied by mucosal 
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involvement and skin detachment. Diagnosis of SJS/TEN had to be assessed with its 
phenotypes based on the criteria of the RegiSCAR study group 11-13. Each enrolled subject 
gave written informed consent, which had been approved by the institutional review 
board (IRB) and ethics committee of our CGMH based on Taiwan law (IRB No.97-0509B, 
No.100-4657A3, No.103-2562C, and No.105-3600C).  Patients’ serum samples during the 
acute, maximum, and recovery stages of SJS/TEN were obtained and frozen at -80 °C. The 
time to onset of the illness in each individual patient was also evaluated. The “acute” stage 
was defined as <6 days from onset of illness; the “maximum” stage was defined as the 
time from onset to maximal skin detachment (without progression of skin detachment); 
the “recovery” stage was defined as the time to complete skin healing.  The purpose of 
analysing this cohort was to determine serum HMGB1 during the acute phase of SJS/TEN 
but also at the maximal point of the reaction and during the recovery phase (both of 
which were determined retrospectively). 
 
 Spanish SJS/TEN and DRESS cohort 
Cases (n=23) diagnosed with SJS, TEN, SJS/TEN or DRESS/SJS/TEN overlap were 
identified in different hospitals in Madrid (Spain) belonging to the PIELenRed consortium 
(Supplementary Table 2). SJS/TEN was characterized purpuric macules and or target-like 
lesions, accompanied by mucosal involvement and skin detachment. Patients were 
classified according to the consensus criteria 14. DRESS was diagnosed according to the 
RegiSCAR scoring system 15 Patient serum and blister fluid samples were obtained at first 
presentation (acute) and frozen at -80°C. The study was approved by the Research Ethics 
Committee of Príncipe de Asturias University Hospital (the coordinating center of the 
PielenRed Consortium). Patients or their legal representatives gave written informed 
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consent.  The purpose of analyzing this cohort was to compare HMGB1 levels during the 
acute phase of SJS/TEN in both serum and blister-fluid. 
 
Formalin-fixed paraffin-embedded skin biopsy tissue samples. 
FFPE skin samples (5 healthy controls, 7 drug-induced rash and 7 SJS/TEN) were 
identified from the histology archive database at Cleveland Clinic, Ohio, USA, from 2013-
16 (accessed January 2017).  An internal diagnosis or description search included the 
terms “Stevens-Johnson Syndrome” or “toxic epidermal necrolysis” and drug eruption/ 
drug reaction (including “dermal hypersensitivity reaction”).  Specific cases were 
selected where a diagnosis of drug-induced SJS/TEN or maculopapular exanthem was 
very strongly favoured and was supported by clinical notes.  For normal healthy control 
samples, normal skin from excision specimens were utilised.  Suspected causal drugs 
were identified from clinical notes. 
 
Serum HMGB1 Measurement 
All serum samples were transferred to the Wolfson Centre for Personalised Medicine, 
University of Liverpool, UK for analysis.  Total HMGB1 protein concentrations in serum 
and blister fluid (where available) were determined by ELISA according to the 
manufacturer’s protocol (Oxford Biosystems, UK).  Spectrophotometric analysis at 
450nm was undertaken using a DTX880 Plate Reader (Beckman Coulter Inc., High 
Wycombe, UK). Blister fluid samples were analysed iteratively, firstly neat and then at 
30-fold and 300-fold dilution in PBS until quantifiable within the detection range of the 
assay.  Sample measurements failing to reach the manufacturer’s lower limit of 
quantification (0.2ng/ml) or where replicates were discordant by >15% were excluded. 
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HMGB1 Immunohistochemistry  
For immunohistochemistry (IHC), sections were dewaxed and subjected to antigen 
retrieval in Dako PT buffer high pH (Agilent Technologies Ltd, UK) using a computer 
controlled antigen retrieval workstation (PT Link; Agilent Technologies Ltd, UK) for 20 
min at 98°C. Sections were then stained in an automated immunostainer (Link 48; 
Agilent Technologies Ltd, UK), using a primary antibody against human HMGB1 (Rabbit 
polyclonal, ab18256, Abcam Ltd, Cambridge, UK,; 1 in 1000) in a 1 h incubation at room 
temperature (RT). This was followed by a 30 min incubation at RT with the polymer 
peroxidase-based detection system (Anti Mouse/Rabbit Envision Flex+, Agilent 
Technologies Ltd, UK). The reaction was visualised with diaminobenzidine (Agilent 
Technologies Ltd, UK). Consecutive sections incubated with non-immune rabbit serum 
served as negative controls. The positive reaction was represented by a distinct brown 
nuclear (or rarely cytoplasmic) reaction. Positive control was represented by epidermis 
and follicle in normal skin. 
 
Semi-quantitative analysis of immunohistochemical HMGB1 expression intensity was 
undertaken by a pathologist with respect to distribution within the epidermal layers but 
also to nuclear staining as follows:  Negative stain (-) was defined as absence of specific 
brown stain. Minimal stain (+/-) was judged as barely visible specific brown stain. 
Moderate stain (+) was judged as clear evident staining which was milder compared to 
the intensity of the keratinocytes of the normal skin.  Strong stain (++) was of an 
intensity compared with the keratinocytes of the normal skin (positive control).  Stain 
intensity category (- ; +/- ; + ; ++) was allocated according to the most represented 
pattern present in the biopsy available on the slide.  
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Statistical Analysis 
Statistical analysis was undertaken using Prism 5 software (GraphPad Inc.) and RStudio 
version 1.1.414.  To analyse the difference in HMGB1 levels between serum and blister 
fluid in the Spanish cohort and difference in HMGB1 levels with time in the Taiwanese 
cohort, linear mixed models were fitted using the lmer function in R package lme4. This 
approach allowed for more than one measurement from the same individual. For the 
Spanish cohort, HMGB1 levels were log-transformed to ensure model residuals were 
normally distributed. Comparison of data between unpaired sample groups (i.e. 
between hypersensitivity phenotypes) was undertaken using a Kruskal-Wallis test. A 
threshold cut-off, based on the recently reported 97.5% quantile reference ranges 16,  
was used to classify samples as elevated (>2.3ng/ml).  Analysis of the resulting binary 
outcome between phenotype groups was by Chi-squared test. To adjust for multiple 
testing, the Bonferroni approach was undertaken, adjusting the p-value threshold for 
nominal significance, 0.05, by the number of tests. Since not all outcomes tested are 
independent (e.g. combined cutaneous hypersensitivity phenotype and the specific 
hypersensitivity reaction phenotype groups), we believe this to be a conservative 
approach.  
 
RESULTS 
Serum and blister fluid HMGB1 concentrations. 
Nevirapine-induced cases and controls:  Of the initially identified 51 nevirapine 
cutaneous hypersensitivity cases and 102 tolerant controls, sera from 40 cases (22 MPE, 
9 DRESS, 9 SJS/TEN) and 70 controls at time of reaction were available for analysis of 
total HMGB1 (Figure 1). Using the Kruskal-Wallis test, we found that mean 
concentrations (±SD) of total HMGB1 in each of the 3 nevirapine-induced cutaneous 
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phenotypes (MPE: 3.92±2.75ng/ml, DRESS: 5.25±2.65ng/ml SJS/TEN: 3.98±2.17 ng/ml,  
and combined (4.17±2.81ng/ml) were higher (though not significantly) than those in 
the tolerant control group (2.97ng/ml±3.00; P>0.05) (Figure 1A).  
Using the Chi-squared test, we found that the percentage of individuals with elevated 
levels above our defined upper limit of normal (ULN) (>2.3ng/ml) was higher in the 
combined cutaneous hypersensitivity (75%, p=0.002), MPE (72%, p=0.027), DRESS 
(89%, p=0.029) and SJS/TEN (78%, p=0.042) compared to the tolerant group (46%).  
Only the combined cutaneous hypersensitivity phenotype remained significant after 
correction for multiple testing (p<0.0125).  
Taiwanese SJS/TEN patients: Serum from 73 Taiwanese SJS/TEN patients was 
analysed for HMGB1 (Figure 2).  This included 73 acute reaction samples, 59 samples at 
time of maximal reaction and 66 samples from the recovery phase.  The mean total 
serum HMGB1 (±SD) during the acute phase of the reaction was 32.6±26.6ng/ml which 
was higher than at both the maximal reaction time (19.7 ±23.2ng/ml; p=0.0002) and 
recovery (24.6ng/ml ±25.3; p=0.0003). Both these differences were statistically 
significant after applying Bonferroni adjustment (p-value threshold 0.017 for three 
pairwise comparisons).  No statistically significant difference was observed between 
maximal reaction and recovery. 
Spanish SJS/TEN patients: The mean serum total HMGB1 (n=22) in the Spanish 
SJS/TEN cohort (Figure 3) was 8.8 ±7.6ng/ml.  Blister fluid levels (n=13) were 
significantly higher at 486.8ng/ml±687.9 (p<0.001) than serum levels.  In the 12 
individuals where samples from both sites were available, there was no correlation 
between matched serum and blister fluid HMGB1 levels (R2=0.036) (data not shown). 
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Skin tissue expression of HMGB1. 
Immunohistochemical staining of FFPE skin sections showed that, compared to healthy 
control and MPE skin, SJS/TEN patients exhibited significantly less nuclear expression 
of total HMGB1 in the epidermis of non-blistered SJS/TEN skin (Figure 4). Indeed, 
expression appeared to be limited to the basal/suprabasal layer (Figure 5), an 
observation that was consistent in all SJS/TEN individuals regardless of the site of 
biopsy. (Table 1). Prominent HMGB1 expression was also observed in infiltrating 
inflammatory cells in the skin from both MPE and SJS/TEN patients. 
 
DISCUSSION 
The data from this study show that total serum HMGB1 levels are elevated in patients 
with SJS/TEN, with levels being higher in blister fluid than in paired serum samples.  
Furthermore, our data highlight the changes occurring in lesional skin from SJS/TEN 
patients with HMGB1 expression being seen in the basal/suprabasal layer, but was 
reduced overall in the epidermis.  However, the elevation in serum HMGB1 may be 
confounded by underlying disease as the effect in Malawian patients with advanced HIV 
disease was absent when compared with non-HIV patients.  
 
In our nevirapine hypersensitivity cohort from Malawi, although HMGB1 levels at the 
time of reaction in SJS/TEN and DRESS patients were elevated, they were not 
significantly higher than those in both tolerant and MPE patients (Figure 1A). Creation 
of a binary outcome with a threshold cut-off (>2.3ng/ml) (Figure 1B) provided some 
indication that HMGB1 may be able to discriminate between phenotypes to a small 
degree, but this is unlikely to be useful clinically.  By contrast, in HIV-negative patients 
with SJS/TEN from both Taiwan and Spain, serum HMGB1 levels were significantly 
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elevated, with levels in the Spanish cohort (8.8ng/ml) similar to that previously 
observed in Japanese SJS/TEN patients at the time of the reaction 7,9.  The HMGB1 
concentrations were much higher in Taiwanese patients  (36.2ng/ml; Figure 2) than in 
the Spanish patients; the reasons for this unclear, but given the small sample sizes, it is 
perhaps best not to over-interpret the differences as these may be due to sample 
collection and storage differences rather than true biological variability.  One variable 
that can be discounted is inconsistency in the SJS/TEN phenotype definition since both 
the Spanish and Taiwanese cohorts utilised the same criteria (RegiSCAR), while in the 
nevirapine cohort from Malawi, the diagnostic criteria are closely aligned.  It is 
important to note that the 3 independent cohorts studied were brought together 
retrospectively, from studies of differing design, to address different questions relating 
to HMGB1 elevation.  This limits our ability to assess differences between the different 
cohorts.   
 
The different results obtained in HIV-positive patients from Malawi compared with the 
HIV-negative patients from Taiwan and Spain may be related to the confounding effect 
of HIV infection.  Our Malawian patients were at an advanced stage of HIV infection (HIV 
clinical stage 3/4 and/or had a CD4+ count <250 cells/µL).  HIV-infection has previously 
been shown to cause elevated HMGB1 serum levels 17, while HMGB1 itself may enhance 
HIV replication 18.  By contrast, HMGB1 levels tend to be reduced by antiretroviral 
therapy (ART), albeit long-term therapy 19, but with little data available over the short-
term particularly in those at more advanced stages of HIV disease 20.  Given the 
confounding effects of HIV disease and concomitant ART, it is perhaps not surprising 
that the total HMGB1 levels were lower than those seen in the Taiwanese and Spanish 
patients, and did not sufficiently distinguish between control, MPE and SJS/TEN 
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patients. Indeed, a significant 46% of tolerant controls exhibited HMGB1 serum levels 
above our nominal ULN (>2.3ng/ml) which further highlights the potential influence of 
co-medication and co-morbidity on serum HMGB1 levels.  It is also important to 
acknowledge that elevation in serum HMGB1 is not specific to cutaneous 
hypersensitivity reactions, and has been observed in HIV17, epilepsy 21 and a number of 
other inflammatory and autoimmune diseases22.   
 
Serum HMGB1 levels in Taiwanese SJS/TEN patients were significantly higher during 
the acute phase of the reaction than at both the maximal and recovery phases (Figure 
2), suggesting activation of this pathway at the time of presentation indicative of tissue 
damage, before treatment (symptomatic and specific) is given that may lead to 
alterations in levels.  Interestingly, for the first time, we have shown that blister fluid 
levels of HMGB1 in SJS/TEN patients were 55-fold higher than in serum indicating that 
voiding of HMGB1 from the keratinocytes in the epidermis is likely to contribute to the 
significantly elevated blister fluid levels (Figure 3).   
 
Our data from skin biopsies showed the previously unreported observation of 
decreased expression of nuclear HMGB1 in the epidermis of pre-blistered SJS/TEN skin 
coupled with the expression of HMGB1 in the basal and suprabasal layers (Figure 5). 
Although this observation has been made in a small sample (n=7) of biopsies from 
SJS/TEN patients, the consistency of the finding across all patients (Table1) would 
suggest that it is a true observation.  Keratinocyte death is likely to explain the decrease 
in epidermal expression, and subsequent increased levels of circulating serum total 
HMGB1.  However, given that, histologically SJS/TEN is characterised by separation of 
the epidermis and dermis, the role of HMGB1 retained at the suprabasal layer warrants 
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further investigation.  The dramatic difference between epidermal distribution of 
HMGB1 in SJS/TEN compared to control and MPE skin makes IHC analysis of HMGB1 a 
potential diagnostic marker for SJS/TEN, but this would require further investigation.  
Interestingly, our data also suggest that keratinocyte release of HMGB1 in SJS/TEN skin 
may occur prior to epidermal detachment (Figure 4) and thus HMGB1 serum elevation 
may actually precede it, raising the possibility that it may represent a good early marker 
of cell death/tissue damage in SJS/TEN.  Again, this will need further study. 
 
Our study is limited by the fact that we have measured total HMGB1 but not its post-
translationally modified HMGB1 acetylated isoform.  In its hyper-acetylated form, 
HMGB1 can be actively secreted from multiple cell types (macrophages, NK cells, 
dendritic cells for example) as part of an innate immune response 23.  Additionally, in its 
un-acetylated form, it can be passively secreted from necrotic or damaged cells with 
both mechanisms leading to significantly elevated extracellular HMGB1 levels 24.  Given 
the activation of the innate immune response in SJS/TEN 25, activated macrophages are 
likely to be a source of HMGB1 (in its acetylated form) 26.  It is entirely plausible that 
elevation of serum un-acetylated HMGB1 (passive released from dying keratinocytes) 
may differentiate between SJS/TEN patients and individuals with milder phenotypes 
(MPE and DRESS) where widespread cell/tissue injury is not observed.  This will 
require careful assessment of the HMGB1 isoforms, which we plan to undertake in the 
near future through the development of a new assay.   
 
Our data suggest that, unlike granulysin and IL15 6, total HMGB1 serum levels do not 
correlate with SJS/TEN severity scores (SCORTEN) (data not shown).  This coupled with 
the observation that levels remain high even in the recovery phase (Figure 2) suggests 
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that its utility as a prognostic marker is likely to be limited.  Furthermore, confounding 
by other concomitant conditions such as HIV infection may lead to changes in HMGB1 
levels which may be difficult to interpret in relation to the occurrence of SJS/TEN.   
However, it is important to note that HMGB1 is associated with different physiological 
functions related to the innate immune response and dependent on its redox state 26,27.  
Consequently, HMGB1 may be important in the pathogenesis of the keratinocyte 
damage seen in SJS/TEN, exacerbated by the infiltration of activated innate and 
adaptive immune cells, and the subsequent localized release of cytotoxic proteins, 
including granulysin to augment keratinocyte injury.  This is perhaps suggested by our 
skin biopsy analyses, but will require further work to fully understand the role of 
HMGB1 in the pathogenesis of SJS/TEN.   
 
In conclusion, this study has shown that HMGB1 is elevated in patients with SJS/TEN, 
with levels being higher in blister fluid than in serum, but this may not be the case in all 
patient groups, particularly where the underlying concomitant disease (for example 
advanced HIV disease as in our Malawian patients) and its treatment can affect HMGB1 
levels.  Our data from skin biopsies also, for the first time, demonstrate that HMGB1 
expression is depleted in the epidermis of SJS/TEN patients, with some HMGB1 being 
retained in the basal layer, in proximity to the epidermal/dermal junction, providing 
suggestive evidence of a putative role for HMGB1 in the pathogenesis of epidermal 
separation, although further work will need to be undertaken to elucidate this. 
 
ACKNOWLEDGEMENTS 
Valerie Tilston from Department of Veterinary Pathology, Institute of Veterinary Science 
for   immunohistochemical staining of tissue sections.  
18 
 
The views expressed in this article are those of the authors and do not necessarily 
reflect the official policy or position of the Department of the Navy, Department of 
Defense, nor the US Government. Dr Shrivastava is a military service member; this work 
was prepared as part of his official duties and as such is not eligible for copyright 
protection. 
  
19 
 
REFERENCES 
1 Frey N, Jossi J, Bodmer M et al. The Epidemiology of Stevens-Johnson Syndrome 
and Toxic Epidermal Necrolysis in the UK. The Journal of investigative 
dermatology 2017. 
2 Kagan RJ, Edelman L, Solem L et al. DRG 272: does it provide adequate burn 
center reimbursement for the care of patients with Stevens-Johnson syndrome 
and toxic epidermal necrolysis? Journal of burn care & research : official 
publication of the American Burn Association 2007; 28: 669-74. 
3 Usui T, Naisbitt DJ. Human leukocyte antigen and idiosyncratic adverse drug 
reactions. Drug metabolism and pharmacokinetics 2017; 32: 21-30. 
4 Chung WH, Hung SI, Yang JY et al. Granulysin is a key mediator for disseminated 
keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. 
Nat Med 2008; 14: 1343-50. 
5 Posadas SJ, Padial A, Torres MJ et al. Delayed reactions to drugs show levels of 
perforin, granzyme B, and Fas-L to be related to disease severity. The Journal of 
allergy and clinical immunology 2002; 109: 155-61. 
6 Su SC, Mockenhaupt M, Wolkenstein P et al. Interleukin-15 Is Associated with 
Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal 
Necrolysis. The Journal of investigative dermatology 2017; 137: 1065-73. 
7 Nakajima S, Watanabe H, Tohyama M et al. High-mobility group box 1 protein 
(HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-
Johnson syndrome. Arch Dermatol 2011; 147: 1110-2. 
8 Andersson U, Antoine DJ, Tracey KJ. The functions of HMGB1 depend on 
molecular localization and post-translational modifications. Journal of internal 
medicine 2014; 276: 420-4. 
9 Fujita H, Matsukura S, Watanabe T et al. The serum level of HMGB1 (high 
mobility group box 1 protein) is preferentially high in drug-induced 
hypersensitivity syndrome/drug reaction with eosinophilia and systemic 
symptoms. The British journal of dermatology 2014; 171: 1585-8. 
10 Carr DF, Chaponda M, Jorgensen AL et al. Association of Human Leukocyte 
Antigen Alleles and Nevirapine Hypersensitivity in a Malawian HIV-Infected 
Population. Clin Infect Dis 2013; 56: 1330-9. 
11 Auquier-Dunant A, Mockenhaupt M, Naldi L et al. Correlations between clinical 
patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, 
and toxic epidermal necrolysis: results of an international prospective study. 
Arch Dermatol 2002; 138: 1019-24. 
12 Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 2005; 
209: 123-9. 
13 Wang CW, Yang LY, Chen CB et al. Randomized, controlled trial of TNF-alpha 
antagonist in CTL-mediated severe cutaneous adverse reactions. The Journal of 
clinical investigation 2018; 128: 985-96. 
14 Bastuji-Garin S, Rzany B, Stern RS et al. Clinical classification of cases of toxic 
epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. 
Arch Dermatol 1993; 129: 92-6. 
15 Kardaun SH, Mockenhaupt M, Roujeau JC. Comments on: DRESS syndrome. J Am 
Acad Dermatol 2014; 71: 1000- e2. 
16 Francis B, Clarke JI, Walker LE et al. Reference intervals for putative biomarkers 
of drug-induced liver injury and liver regeneration in healthy human volunteers. 
Journal of hepatology 2018. 
20 
 
17 Nowak P, Barqasho B, Sonnerborg A. Elevated plasma levels of high mobility 
group box protein 1 in patients with HIV-1 infection. AIDS 2007; 21: 869-71. 
18 Trinh QD, Pham NT, Fuwa K et al. High Mobility Group Box 1 Protein Enhances 
HIV Replication in Newly Infected Primary T Cells. Clinical laboratory 2016; 62: 
2305-11. 
19 Troseid M, Nowak P, Nystrom J et al. Elevated plasma levels of 
lipopolysaccharide and high mobility group box-1 protein are associated with 
high viral load in HIV-1 infection: reduction by 2-year antiretroviral therapy. 
AIDS 2010; 24: 1733-7. 
20 Tasca KI, Caleffi JT, Correa CR et al. The Initial Months of Antiretroviral Therapy 
and Its Influence on AGEs, HMGB1, and sRAGE Levels in Asymptomatic HIV-
Infected Individuals. Mediators of inflammation 2016; 2016: 2909576. 
21 Zhu M, Chen J, Guo H et al. High Mobility Group Protein B1 (HMGB1) and 
Interleukin-1beta as Prognostic Biomarkers of Epilepsy in Children. Journal of 
child neurology 2018; 33: 909-17. 
22 Magna M, Pisetsky DS. The role of HMGB1 in the pathogenesis of inflammatory 
and autoimmune diseases. Molecular medicine 2014; 20: 138-46. 
23 Harris HE, Andersson U, Pisetsky DS. HMGB1: a multifunctional alarmin driving 
autoimmune and inflammatory disease. Nature reviews. Rheumatology 2012; 8: 
195-202. 
24 Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic 
cells triggers inflammation. Nature 2002; 418: 191-5. 
25 Abe R. Immunological response in Stevens-Johnson syndrome and toxic 
epidermal necrolysis. The Journal of dermatology 2015; 42: 42-8. 
26 Yang H, Antoine DJ, Andersson U et al. The many faces of HMGB1: molecular 
structure-functional activity in inflammation, apoptosis, and chemotaxis. Journal 
of leukocyte biology 2013; 93: 865-73. 
27 Schiraldi M, Raucci A, Munoz LM et al. HMGB1 promotes recruitment of 
inflammatory cells to damaged tissues by forming a complex with CXCL12 and 
signaling via CXCR4. The Journal of experimental medicine 2012; 209: 551-63. 
 
 
 
21 
 
 
TABLES 
Table 1. Semi-quantitative analysis of HMGB1 IHC staining in healthy, MPE and SJS/TEN skin biopsy sections from the Cleveland Clinic 
archival cohort. N.P. denotes not present in the biopsy section analysed. Intensity: (-)=negative; (-/+) =minimal;  (+) = moderate;  
(++)=strong. 
 
     
IHC HMGB1 Expression 
Phenotype Biopsy Site Age Gender Causal Drug Epidermis 
Nuclear stain 
within Epidermis 
Follicle/ 
Adnexae Dermis 
Inflammatory 
Infiltrate 
Healthy Thigh 23 F  n/a ++ all layers ++ +/- N.P. 
Healthy Forehead 19 M  n/a ++ all layers ++ + N.P. 
Healthy Arm 61 F  n/a ++ all layers ++ +/- N.P. 
Healthy Back 58 F  n/a ++ all layers ++ +/- N.P. 
Healthy Inferior Breast 40 F  n/a ++ all layers N.P. + N.P. 
MPE Arm 81 F vancomycin + all layers ++ + ++ 
MPE Arm 61 M meropenem ++ all layers ++ +/- ++ 
MPE Arm 59 F simvastatin ++ all layers ++ +/- ++ 
MPE Arm 22 M apiprazole ++ all layers ++ +/- ++ 
MPE Scalp 78 F undetermined ++ all layers ++ +/- ++ 
MPE Abdomen 59 F levetiracetam ++ all layers ++ + ++ 
MPE Abdomen 62 M piperacillin /tazobactam ++ all layers ++ + ++ 
SJS Back 62 M ceftaroline +/- Basal/Suprabasal layer ++ +/- ++ 
SJS Arm 51 M vancomycin +/- Basal/Suprabasal layer N.P. +/- ++ 
SJS Lip 23 F sulfamethoxazole/ trimethoprim +/- Basal/Suprabasal layer N.P. + ++ 
SJS/TEN Thigh 54 M vancomycin +/- Basal/Suprabasal layer ++ +/- ++ 
SJS/TEN Abdomen 39 F piperacillin/ tazobactam +/- Basal/Suprabasal layer ++ +/- ++ 
TEN Arm 24 F ketorolac +/- Basal/Suprabasal layer +/- - ++ 
TEN Chest 28 F sulfamethoxazole/ trimethoprim +/- Basal/Suprabasal layer ++ +/- ++ 
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FIGURE LEGENDS 
Figure 1. Serum total HMGB1 concentration in the Malawian, nevirapine-exposed HIV cohort at 
time of reaction. A) represents concentration (ng/ml) for different cutaneous hypersensitivity 
phenotypes (2 weeks after drug initiation for tolerant). The dashed line indicates the defined 
ULN (2.3ng/ml). B) shows the number of individuals whose serum concentration was above 
the ULN (black bars) or below the ULN (grey bars). Statistical significance, determined by 
Kruskal-Wallis test (A) and Chi-squared (B) is indicated by * (p<0.05), **(p<0.01). 
 
Figure 2. Total HMGB1 in serum from the Taiwanese SJS/TEN cohort during the acute phase of 
the reaction; maximal point of reaction and during the recovery phase. The dashed line 
indicates the notional ULN (2.3ng/ml). Statistical significance, determined by linear mixed 
modelling is indicated by *** p<0.001). 
 
Figure 3. Total HMGB1 in serum and blister fluid from the Spanish SJS/TEN cohort at time of 
reaction.  The dashed line indicates the notional ULN (2.3ng/ml). Statistical significance, 
determined by linear mixed modelling is indicated by *** (p<0.001). Circles represent SJS/TEN 
cases and triangles DRESS/TEN overlap. 
 
Figure 4. Immunohistochemical staining of HMGB1 in healthy, maculopapular exanthema and 
SJS/TEN skin.  (100X magnification).   
 
Figure 5. HMGB1 staining at the epidermal basal/suprabasal layer in healthy, maculopapular 
exanthema and SJS/TEN skin.  Black arrow indicates the stratum basale; white arrow the 
stratum spinosum and arrowhead the inflammatory infiltrate.  The dashed line indicates the 
dermal/epidermal junction. (400X magnification). 
